Volume 5.42 | Oct 24

Cord Blood News 5.42 October 24, 2013
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
 
TOP STORY
Molecule Increases Growth of Stem Cells, Research Suggests
Recently published results from the Harvard Stem Cell Institute’s first-ever clinical trials have identified a molecule that could increase the success rates of umbilical cord blood transplants in cancer patients. The trials found that umbilical cord blood cells treated with 16, 16-dimethyl prostaglandin E2, a molecule derived from fatty acids and also called dmPGE2, grew more stem cells than untreated umbilical cord blood. [Press release from The Harvard Crimson discussing research published in Blood] Press Release | Abstract
Learn how to complete, submit and review BMT registry forms locally. Join the Webinar.
 
PUBLICATIONS (Ranked by impact factor of the journal)
Modeling the Sitagliptin Effect on Dipeptidyl Peptidase-4 Activity in Adults with Hematological Malignancies After Umbilical Cord Blood Hematopoietic Cell Transplantation
This clinical study included 24 patients who received myeloablative conditioning followed by oral sitagliptin with single-unit umbilical cord blood hematopoietic cell transplantation. Using a nonlinear mixed-effects approach, a semi-mechanistic pharmacokinetic-pharmacodynamic model was developed to describe dipeptidyl peptidase-4 activity from these trial data, using NONMEM version 7.2 software. [Clin Pharmacokinet] Abstract

Effect of Mesenchymal Stem Cells and Extracts Derived from the Placenta on Trophoblast Invasion and Immune Responses
Investigators analyzed the effects of chorionic plate-derived mesenchymal stem cells and human placenta extract isolated from human normal placentas on trophoblasts invasion and immune responses. [Stem Cells Dev] Abstract

CD146+ Human Umbilical Cord Perivascular Cells Maintain Stemness under Hypoxia and as a Cell Source for Skeletal Regeneration
Human umbilical cord perivascular cells (HUCPVCs) were isolated and sorted by CD146+ pericyte marker. The purified CD146+ HUCPVCs were induced to differentiate efficiently into osteoblast, chondrocyte and adipocyte lineages in vitro. [PLoS One] Full Article

Mesenchymal Stem Cells from Umbilical Cord Matrix, Adipose Tissue and Bone Marrow Exhibit Different Capability to Suppress Peripheral Blood B, Natural Killer and T Cells
Investigators evaluated the influence of human mesenchymal stem cells derived from umbilical cord matrix, bone marrow and adipose tissue, co-cultured with phytohemagglutinin-stimulated peripheral blood mononuclear cells, on T, B and natural killer (NK) cell activation; T and B cells’ ability to acquire lymphoblast characteristics; mRNA expression of interleukin-2, forkhead box P3, T-bet and GATA binding protein 3, on purified T cells, and tumor necrosis factor-alpha, perforin and granzyme B on purified NK cells. [Stem Cell Res Ther] Abstract | Full Article

Combination of a Haploidentical SCT with an Unrelated Cord Blood Unit: A Single-Arm Prospective Study
Scientists conducted a single-arm prospective study in 50 patients who received the combination of an haploidentical stem cell graft and an unrelated umbilical cord blood unit for the treatment of hematological malignancies. [Bone Marrow Transplant] Abstract

Mesenchymal Stem Cell Isolation from Human Umbilical Cord Tissue: Understanding and Minimizing Variability in Cell Yield for Process Optimization
Cell yield, growth, and differentiation potential of umbilical cord tissue extracted cells was analyzed from tissue processed by explant and enzymatic digestion. [Biopreserv Biobank] Abstract

Detection of Cytokines in Supernatant from Hematopoietic Stem/Progenitor Cells Co-Cultured with Mesenchymal Stem Cells and Endothelial Progenitor Cells
Researchers aimed to investigate the significance of cytokine expression in supernatant from hematopoietic stem/progenitor cells co-cultured with mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs). Mononuclear cells were isolated from normal human umbilical cord blood and then cultured solely or co-cultured with MSCs or EPCs. [Cell Tissue Bank] Abstract

FREE Technical Resource: Atlas of Hematopoietic Colonies from Cord Blood. Request your copy.
 
REVIEWS
Applications of Human Hematopoietic Stem Cells Isolated and Expanded from Different Tissues in Regenerative Medicine
The authors describe the current methodologies for isolating and processing hematopoietic stem cells (HSCs) from various tissues, and discussed strategies to generate sufficient and functional HSCs for clinical and preclinical applications by expansion ex vivo. [Regen Med] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
 
INDUSTRY NEWS
Cellular Dynamics Issued U.S. Patent Covering Differentiation of iPS Cells into Endothelial, Hematopoietic Cells
Cellular Dynamics International announced that the U.S. Patent and Trademark Office issued Patent No. 8,557,580 entitled “Methods and Compositions for the Differentiation of Stem Cells”. The newly issued patent relates to the method by which induced pluripotent stem (iPS) cells are differentiated into the diverse types of endothelial and hematopoietic cells. [Cellular Dynamics International] Press Release

Einstein and Montefiore Receive $25 Million NIH Grant to Support Clinical and Translational Research
Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have received a $25 million grant from the National Institutes of Health (NIH) for the Harold and Muriel Block Institute for Clinical and Translational Research at Einstein and Montefiore. The two institutions received their initial Clinical and Translational Science Award from the NIH in 2008 to launch this joint collaboration. [Albert Einstein College of Medicine] Press Release

STEMSOFT Licenses StemLab Software to TUMCells
STEMSOFT™ Software Inc. (STEMSOFT) announced the licensing of StemLab™, the leading cell therapy transplant laboratory software, to TUMCells Interdisziplinäres Zentrum für zelluläre Therapien Technische Universität München (TUMCells) at the University Hospital Klinikum rechts der Isar in Germany. [STEMSOFT Software Inc.] Press Release

Enter Our Contest  
Cord Blood News is giving away a free registration for the World Stem Cell Summit 2013 in San Diego! Click here to enter “Your Window to the World of Regenerative Medicine”.

 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.
 
EVENTS
NEW Strategies to Inhibit Graft-versus-Host Disease While Sparing the Graft-versus-Tumor Response: Finding the Sweet Spot
February 18, 2014
New York City, United States

Visit our events page to see a complete list of events in the cord blood community.
 
JOB OPPORTUNITIES
NEW PhD Studentship – Identifying Drugs to Improve the Utility of Bone Marrow and Cord Blood Transplantation (Cardiff University)

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Postdoctoral Position – Patient-Specific Stem Cell Lines: Disease Modeling, Repair and Transplantation (Columbia University)

Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

Postdoctoral Position – Immune Recovery after Hematopoietic Stem Cell Transplantation (University of Minnesota – Twin Cities)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Postdoctoral Fellow – Differentiation of Erythrocytes and Endothelial Cells from Hemangioblast (University of Rochester)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Cord Blood News: Archives | Events | Contact Us